Is an Estrogen Patch Safer Than Oral Estradiol for Blood Clots?

An estrogen patch is linked to a lower blood clot risk than oral estradiol. Estrogen absorbed through the skin skips the liver, while a pill goes to the liver first. In a pooled analysis, women taking oral hormone therapy had about 2.5 times the odds of a clot compared with women who never used hormones, while women using transdermal estrogen (estrogen through the skin) showed no statistically significant increase. Both forms ease hot flashes, so the choice comes down to your clot risk, your dose and what else you want from treatment.

Why does an estrogen pill affect your liver when a patch doesn't?

When you swallow an estradiol pill, it is absorbed from your gut and passes through your liver before it reaches the rest of your body. A patch or gel delivers estradiol through your skin straight into your blood. Skipping the liver this way keeps estradiol levels steadier and avoids very high levels inside the liver.

That first pass through the liver makes it produce more of certain proteins. With the pill, these include clotting factors and CRP, a marker of inflammation. With transdermal estrogen, these changes are smaller.

One small trial shows the route matters more than the amount of estrogen in your blood. In a 12-week trial of 27 postmenopausal women, a 2 mg estradiol pill and a 50 microgram patch raised free estradiol by similar amounts. Only the pill pushed clotting markers toward faster clotting and raised CRP. The patch changed none of them. The authors concluded that the route drove the difference, not the estrogen level in the blood.

Through the skin, a lower dose does the job, and estrone stays closer to premenopausal levels. Estrone is a weaker estrogen your body makes from estradiol.

How much lower is the blood clot risk with a patch?

A venous blood clot is a clot in a vein, such as in your leg or lung. In a 2008 pooled analysis cited by a later systematic review, oral hormone therapy was linked to 2.5 times the odds of a venous clot compared with women who never used hormones. For transdermal estrogen the figure was 1.2, and that was not a statistically significant increase.

The gap was widest in women born with a clotting gene mutation. In the studies the review cites, oral hormone therapy was linked to a 25-fold higher clot risk than in nonusers. With transdermal estrogen the increase was about fourfold.

Of ten studies comparing the two routes, only two found no difference. The rest found transdermal estrogen the safer choice, especially for women already at higher risk of clots. The review called clot risk the clearest difference between pill and patch.

Most of this evidence comes from observational studies rather than randomized trials, and the review rated the overall evidence comparing routes as limited and low quality. The direction has stayed consistent across studies. The exact size of the gap is the less certain part.

Does a higher-dose patch lose the advantage?

It can. Dose matters as well as route. In a large UK study of women whose average age was 70, a low-dose patch (50 micrograms or less) was not linked to a higher stroke risk, though the authors could not rule out a slight rise with long-term use. High-dose patches and oral hormone therapy raised stroke risk by 25% to 88%.

The Menopause Society's 2022 position statement reaches the same conclusion for clots and stroke: transdermal routes and lower doses may lower the risk.

The label for Climara, a once-weekly estradiol patch, says to start at 0.025 mg a day and to adjust the dose based on how you respond. In practice, you start low and let your symptoms guide any change.

What does the pill do better than the patch?

On several outcomes the two forms come out similar. A systematic review found pill and patch similar for hot flash relief, bone density, blood sugar and cholesterol improvement. It found no clear difference in breast cancer, uterine lining disease or heart attack risk.

The pill's advantage is cholesterol. In the 12-week trial, only the pill lowered LDL and lipoprotein(a) and raised HDL. A review found that both routes improve the ratio of HDL to LDL and that the pill does more. The patch did better on triglycerides.

The patch has an extra advantage if you care about your weight and your sex drive. The same review found metabolic syndrome and weight gain slightly less common with transdermal estrogen. It also found that the pill raises SHBG, a liver protein that binds testosterone and leaves less of it available to you. The authors linked this to a clinically relevant effect on sexual vigor. If you want your sex drive back along with fewer hot flashes, that difference is worth raising with your clinical team.

Who should still be careful on an estrogen patch?

A patch still carries the boxed warning, the FDA's strongest label warning, for endometrial cancer, heart and blood vessel problems, probable dementia and breast cancer. The label notes that those study results came from daily oral conjugated estrogens, so it is not known how they apply to other routes.

Tell your clinical team about anything that raises your clot risk, such as a past clot of your own, a clot in your family, obesity or lupus. If you have a uterus, the label says to consider adding a progestogen, such as progesterone, to protect your uterine lining.

Some women are told the pill is off the table entirely. One woman on Reddit wrote: "I’m not allowed to take oral estrogen, so that isn’t even something I can consider."

For most healthy women with symptoms who are under 60 and within 10 years of their last period, the benefits of hormone therapy outweigh the risks. Our clinical team can prescribe bioidentical estrogen if it fits your goal and your clot risk.

You want your hot flashes to settle without adding to your clot risk. Take the quiz so your clinical team can look at your history and see whether bioidentical estrogen fits your plan, and in which form.